Gatifloxacin — Compare Prices at US & Canada Pharmacies

• Levofloxacin is a fluoroquinolone antibiotic effective against many bacterial infections, but carries risk of serious, potentially permanent adverse effects including tendon rupture, nerve damage, and central nervous system complications.
• Frequently reported mild side effects comprise stomach upset, sleep disturbances, mood changes, and increased sun sensitivity, though severe effects may be disabling or irreversible.
• The FDA has strengthened black box warnings for levofloxacin due to documented cases of tendon injury, peripheral nerve damage, and psychiatric effects that can persist or emerge months after treatment ends.
• Risk mitigation involves strict adherence to prescribed dosing, awareness of problematic drug combinations, careful sun protection, and immediate medical attention if symptoms of tendon injury, nerve damage, or severe allergic reaction develop.

Levofloxacin belongs to the fluoroquinolone class of antibiotics, which work by inhibiting bacterial enzymes required for DNA synthesis and replication. Related drugs in this family include ciprofloxacin, ofloxacin, and moxifloxacin. You may have seen or heard this drug referred to by the brand name Levaquin, which was manufactured by Janssen Pharmaceuticals but is now discontinued in the United States.

Fluoroquinolones are potent broad-spectrum agents used for bronchitis, sinus infections, pneumonia, sexually transmitted infections, prostatitis, urinary tract infections, skin infections, and serious conditions like anthrax and plague. The FDA has approved levofloxacin for adults and, in select circumstances, children as young as one month. It is available only by prescription in tablet, oral solution, or injectable form.

This article reviews documented side effects, safety warnings, and drug interactions associated with levofloxacin, along with practical strategies to reduce risks during treatment.

Many patients taking levofloxacin experience mild side effects that typically resolve without intervention. Notify your healthcare provider if any of the following become bothersome during your course of treatment:

Gastrointestinal disturbances such as nausea, vomiting, indigestion, diarrhea, constipation, or abdominal discomfort. General systemic symptoms including headache, dizziness, restlessness, lightheadedness, or confusion. Insomnia or vivid nightmares. Mood and behavioral changes such as anxiety, nervousness, agitation, confusion, delirium, paranoia, or hallucinations. Vaginal inflammation, unusual discharge, or itching. Photosensitivity reactions and skin manifestations such as rashes or pruritus. Tendon tenderness or inflammation. Attention problems or memory impairment. Involuntary muscle contractions or tremor. Elevated blood glucose levels.

A 2016 FDA safety review established that systemic fluoroquinolone exposure can cause rare but potentially permanent and disabling effects affecting the tendons, muscles, joints, peripheral and central nervous systems. These serious reactions have been documented to occur simultaneously—for example, tendinitis occurring alongside tendon rupture, multiple nerve injuries, or combined CNS effects. If you develop any of these serious symptoms while taking levofloxacin, contact your healthcare provider immediately; discontinuation is typically necessary, and further fluoroquinolone use is generally avoided.

Peripheral nerve involvement may produce numbness, tingling, or "pins and needles" sensations in the extremities. Musculoskeletal injuries include tendon inflammation, complete tendon rupture, muscular weakness, joint pain, swelling, or arthropathy. CNS effects encompass elevated intracranial pressure and seizures. Psychiatric effects may include severe psychosis, suicidal ideation, and depressive episodes. Myasthenia gravis symptoms can worsen. Hypersensitivity reactions range from severe skin eruptions to anaphylaxis, jaundice, and serum sickness. Cardiovascular complications include aortic dissection, aortic aneurysm, and vascular inflammation. Rhythm disturbances involve irregular heartbeat, QT prolongation, or torsades de pointes. Severe hypoglycemia can occur. Blood disorders such as abnormal blood counts or bone marrow suppression may develop. Kidney injury can result from crystal precipitation in renal tubules (crystalluria) or direct nephrotoxic injury. Secondary bacterial infections, including Clostridium difficile–associated diarrhea, may emerge. Liver toxicity may present with hepatitis symptoms. Light-induced skin injury (phototoxicity) and uveal inflammation causing red, painful eyes and blurred vision are also possible.

Levofloxacin and related fluoroquinolones can exacerbate muscle pain, weakness, and fatigue in patients with myasthenia gravis or unmask undiagnosed disease. The underlying mechanism involves oxidative stress and mitochondrial injury within muscle cells, leading to impaired neuromuscular transmission, reduced muscle function, and possible muscle tissue loss manifesting as weakness or discomfort.

Because fluoroquinolones are routinely contraindicated in myasthenia gravis, documented cases remain limited. A retrospective analysis identified levofloxacin involvement in nine of 37 reported cases of worsening disease. Importantly, muscle symptoms typically improve rapidly once the antibiotic is stopped. Contact your healthcare provider if muscle pain or weakness develops during fluoroquinolone therapy.

Fluoroquinolones, including levofloxacin, carry well-documented risk of tendon rupture—a severe, potentially disabling injury that may occur alongside tendinitis, peripheral nerve damage, and multiple CNS effects. Rupture can develop during active treatment or even several months after therapy concludes.

Tendon rupture risk rises across all age groups and escalates with higher doses, age over 60 years, concurrent corticosteroid use, and a history of kidney, cardiac, or lung transplantation. Use should stop immediately if rupture or related injuries occur; future fluoroquinolone exposure is typically avoided. A UK study documented 4,836 tendon rupture events among 1,351,780 adult patients treated with fluoroquinolones, highlighting the substantial clinical burden of this complication.

Kidney injury represents an uncommon but serious complication of fluoroquinolone treatment. While precise incidence rates remain unclear, research in U.S. men showed a 2.18-fold elevated relative risk of kidney injury associated with fluoroquinolone use compared to no exposure. Crystal-induced acute kidney injury results when drug crystals precipitate inside kidney tubules, causing obstruction and inflammation.

Risk factors include pre-existing renal impairment, high levofloxacin doses, and advanced age. Kidney function may begin improving within days of stopping the drug, but prompt notification of your healthcare provider is essential if you notice decreased urine output, changes in urine color or clarity, or other urinary or kidney-related symptoms.

True allergic responses to levofloxacin are uncommon, yet hypersensitivity reactions to quinolone antibiotics have increased in frequency. Exact prevalence in the general population is unclear; however, one institutional review published in the International Journal of Clinical Pharmacy reported a 2% quinolone allergy rate among hospitalized patients.

While severe, life-threatening allergic reactions to fluoroquinolones like levofloxacin are rare, recognizing signs of anaphylaxis is critical. Seek immediate medical attention if you experience hives or itchy rash, facial or subcutaneous swelling, paleness or clammy skin, flushing with fever or unprovoked sweating, itching or swelling of eyes, nose, tongue, lips, or mouth, nausea or vomiting with severe abdominal pain, breathing difficulty or wheezing, trouble swallowing or speaking, rapid or weak pulse, fainting or loss of consciousness, or mental confusion or agitation.

Report any adverse events to the FDA by calling 1-800-FDA-1088.

Levofloxacin is contraindicated for use unless there are no other treatment options available for individuals older than 60 years of age, due to dramatically elevated risk of severe tendon disorders and rupture. Risk intensifies when older patients also take corticosteroids. Immediate medical evaluation is warranted if symptoms of tendonitis or rupture appear.

Post-marketing reports document severe, occasionally fatal liver injury in older adults taking fluoroquinolones. Discontinue use immediately if fever, fatigue, appetite loss, nausea, darkened urine, pale stools, or jaundice develop.

Seniors face heightened risk of QT interval–related heart problems, particularly those taking Class IA or Class III antiarrhythmics or with risk factors for torsades de pointes (known QT prolongation or low serum potassium or magnesium). Because levofloxacin is substantially excreted by the kidneys and older adults typically have reduced renal function, careful consideration and possible dose adjustment are necessary in this population.

Side effects generally emerge shortly after the first dose and may persist throughout treatment. While mild effects (nausea, vomiting, diarrhea) and even some serious ones (cardiac disturbances) often resolve after discontinuation, certain severe effects may be permanent (tendon rupture, nerve damage) or fatal (anaphylaxis). Notably, tendinitis and tendon rupture have been reported to occur even in the months after treatment with levofloxacin has been discontinued.

Immediate discontinuation is necessary if symptoms of peripheral nerve injury or hypersensitivity develop.

Levofloxacin is not habit-forming and carries no addiction potential. No withdrawal symptoms have been documented upon discontinuation. Nonetheless, consult your healthcare provider before stopping any medication on your own.

Maximum levofloxacin doses vary by indication and, in pediatric patients, by weight; generally, single doses do not exceed 750 mg. This antibiotic should only be taken at the exact dose, formulation, and frequency prescribed. Exceeding the prescribed amount risks acute kidney failure or serious intestinal infection caused by Clostridium difficile.

Levofloxacin is restricted in certain populations and carries an FDA black box warning—the agency's most serious warning category—highlighting potential for serious injury or death.

Levofloxacin is contraindicated in patients with hypersensitivity to fluoroquinolones, myasthenia gravis, prolonged QT segment on electrocardiogram, or significant uncorrected electrolyte disturbances.

Use is contraindicated unless no alternative exists in patients over 60 years, those with personal or family history of aortic aneurysm, peripheral atherosclerotic vascular disease, hypertension, Marfan syndrome, or Ehlers-Danlos syndrome.

The FDA added a black box warning for fluoroquinolones, including levofloxacin, regarding tendinitis and tendon rupture in July 2008. A warning about myasthenia gravis symptom worsening was added in 2011. In 2013, labeling was updated to include risk of irreversible peripheral neuropathy. The 2016 FDA determination mandated that fluoroquinolones be reserved for patients without alternatives for chronic bronchitis, sinusitis, and uncomplicated urinary tract infections. In 2018, additional safety label changes required warnings about mental health effects and hypoglycemic coma risk.

Fluoroquinolones are associated with tendinitis, tendon rupture, peripheral neuropathy, and CNS effects that may occur concurrently. These serious effects may develop during or months after discontinuation. Risk increases in all populations, especially those over 60, taking corticosteroids, or with kidney, cardiac, or lung transplant history. Discontinue immediately and avoid future fluoroquinolone exposure in patients experiencing adverse reactions.

Fluoroquinolones may worsen muscle weakness in myasthenia gravis patients.

Fluoroquinolone use should be limited to patients with no alternative options for acute bacterial exacerbation of chronic bronchitis, uncomplicated urinary tract infections or cystitis, and acute bacterial sinusitis.

Animal studies at high doses did not demonstrate teratogenic effects, but adequate human pregnancy studies are lacking. Pregnant women should discuss the risk-benefit ratio with their healthcare provider before initiating levofloxacin.

Based on limited levofloxacin data and broader fluoroquinolone experience, the drug enters breast milk. Breastfeeding should be avoided during treatment and for up to two days after discontinuation due to increased infant risk of Clostridium difficile–associated diarrhea. When fluoroquinolones are used to treat maternal anthrax exposure, avoidance of breastfeeding for three to four hours post-dose may be considered.

Quinolones cause arthropathy and osteochondrosis in juvenile animals across multiple species and have demonstrated musculoskeletal toxicity in pediatric clinical studies. Children should receive levofloxacin only for inhalational anthrax, pneumonic or septicemic plague, Yersinia pestis prophylaxis, or serious infections in monitored settings. The risk-benefit profile must be carefully evaluated in any pediatric patient. Safety and efficacy in children under six months have not been established.

Levofloxacin interacts with numerous medications. Use caution when combining levofloxacin with the following agents:

Antacids, magnesium supplements, aluminum preparations (including sucralfate), and didanosine all contain multivalent cations that reduce levofloxacin absorption. Separate levofloxacin administration by at least two hours from these products.

Warfarin is an anticoagulant used to prevent thromboembolism. Concurrent use with levofloxacin can intensify anticoagulation, resulting in serious bleeding. Unless prothrombin time can be monitored every 48 hours, levofloxacin is generally avoided in warfarin-treated patients.

Levofloxacin may raise blood levels of certain diabetes medications. Patients taking oral antidiabetic drugs should inform their healthcare provider before starting levofloxacin and expect close glucose monitoring throughout treatment to prevent dangerous hypoglycemia.

Common over-the-counter pain relievers are NSAIDs. Combined use with levofloxacin or other fluoroquinolones may elevate the risk of serious CNS toxicity and seizures. Inform your healthcare provider of any pain medications or other drugs you start taking after beginning levofloxacin.

Levofloxacin is absolutely contraindicated with cisapride, dronedarone, pimozide, and thioridazine.

Take only the dose prescribed; do not exceed or reduce it. Complete the full course as directed, even if you feel better after the first few doses. If a dose is missed, take it as soon as you recall, then resume your normal schedule.

Levofloxacin appears on the LASA (look-alike, sound-alike) drug list and may be confused with ciprofloxacin, gatifloxacin, levetiracetam, levocarnitine, levodopa, and levothyroxine. Verify your prescription label before taking any dose.

Include all prescription and over-the-counter drugs, supplements, current medical conditions, and any prior medication allergies.

Keep levofloxacin at room temperature (68–77°F) away from direct ultraviolet light.

Do not crush, break, chew tablets, or dilute liquid formulations.

Food does not significantly alter levofloxacin's total absorption but slightly slows the rate at which the drug enters your bloodstream.

Dairy, high-calcium, and calcium-fortified foods can delay levofloxacin absorption. Separate these foods from the medication by at least two hours before and after dosing.

Magnesium- and aluminum-containing antacids impair levofloxacin absorption. Discuss alternative antacid options with your healthcare provider if you require such treatment during levofloxacin therapy.

Most bacterial infections are treated with daily levofloxacin dosing for three to 14 days.

Levofloxacin increases photosensitivity, raising sunburn risk. Apply sunscreen when outdoors and wear protective clothing such as hats and long sleeves during treatment.

Fluoroquinolone hypersensitivity can be life-threatening and requires urgent evaluation and treatment.

Gatifloxacin is a fluoroquinolone-class antibiotic designed specifically for eye infections. It treats bacterial conjunctivitis and other susceptible bacterial infections of the eye by inhibiting bacterial growth. The medication is approved for use in adults and children age 1 year and older. Gatifloxacin eye drops are only available as a 0.5% ophthalmic solution and should be used exactly as directed by your doctor.

Common side effects of gatifloxacin eye drops include eye redness, itching, and excessive tearing. Some patients also report blurred vision, mild eye pain, swollen eyelids, or discharge from the eye. Less frequent side effects include headache, an unpleasant taste in the mouth, and subconjunctival hemorrhage (small broken blood vessels on the white of the eye). Notify your doctor if any of these effects persist or worsen.